Share this article on your favorite social media channel.
The good market situation means that the pharmaceutical industry currently requires capacity at short notice and that it is increasingly outsourcing tasks again. UFAG LABORATORIEN has prepared for this situation and – in addition to increases in terms of staff – has initiated further steps to boost laboratory capacity. Its laboratory extension should be completed by autumn 2007. During this process, corporate growth will continue in a controlled manner. The main focus will remain on the advantages a small company can offer customers, namely quality, personal customer care and professionally competent, individual advice.
Over the past decade, Switzerland as a business location has changed dramatically and consistently aimed to meet European and global requirements.
High tariffs in the analytical services sector in particular have been reduced. UFAG LABORATORIEN is in a position to compete on the European and international markets.
Switzerland has always been a significant location for the international pharmaceutical industry. The borders of Switzerland, France and Germany meet at the Dreiländereck in Basel, a city where several major pharmaceutical groups and their production operations are based. In addition, over the past years, US companies have increasingly moved their production sites and even headquarters to North-Western and Western Switzerland. Structures and processes are today aimed at competitive service output on the market and at UFAG LABORATORIEN establishing itself as a service provider at an international level.
You will find an informative profile of the company in the latest edition of pharmind (issue 4/07).
For enquiries concerning the article, please contact the author by calling our service desk.